Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Altered blood-brain barrier transport of nanotherapeutics in lysosomal storage diseases
Abstract Treatment of neurological lysosomal storage disorders (LSDs) are limited because
of impermeability of the blood-brain barrier (BBB) to macromolecules. Nanoformulations …
of impermeability of the blood-brain barrier (BBB) to macromolecules. Nanoformulations …
[HTML][HTML] Role of the Lactide: Glycolide ratio in PLGA nanoparticle stability and release under lysosomal conditions for enzyme replacement therapy of lysosomal …
M Del Moral, M Loeck, E Muntimadugu, G Vives… - Journal of Functional …, 2023 - mdpi.com
Prior studies demonstrated that encapsulation in poly (lactic-co-glycolic acid)(PLGA)
nanoparticles (NPs) enhanced the delivery of enzymes used for replacement therapy (ERT) …
nanoparticles (NPs) enhanced the delivery of enzymes used for replacement therapy (ERT) …
Effect of acid sphingomyelinase deficiency in type A Niemann-Pick disease on the transport of therapeutic nanocarriers across the blood–brain barrier
ASM deficiency in Niemann-Pick disease type A results in aberrant cellular accumulation of
sphingomyelin, neuroinflammation, neurodegeneration, and early death. There is no …
sphingomyelin, neuroinflammation, neurodegeneration, and early death. There is no …
[HTML][HTML] Tuning Design Parameters of ICAM-1-Targeted 3DNA Nanocarriers to Optimize Pulmonary Targeting Depending on Drug Type
3DNA holds promise as a carrier for drugs that can be intercalated into its core or linked to
surface arms. Coupling 3DNA to an antibody targeting intercellular adhesion molecule 1 …
surface arms. Coupling 3DNA to an antibody targeting intercellular adhesion molecule 1 …